Treatment of Malignant Astrocytomas

Stage, William S.; Stein, Justin J.

doi:10.2214/ajr.120.1.7

Cited by 79 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the 51-55 age group is taken to be the maximum age group, the period of survival tended to be shorter in the younger groups. Glioma is said to be generally more benign in the younger age groups (Stage et al 1974), but the relationship between the degree of malignancy and the patient's age was obscure in this study.…”

Section: *mentioning

confidence: 63%

Statistical analysis of factors affecting survival after glioblastoma multiforme

Takeuchi

Hoshino

1977

Acta neurochir

View full text Add to dashboard Cite

Statistical evaluation of 71 cases (adults) of histologically confirmed supratentorial surgically treated glioblastoma multiforme seen during the period 1958 to 1973 revealed that the state of calcification as determined by roentgenography and the histological appearance of the neoplasm appeared to have a relationship with the postoperative period of survival. Postoperative adjuvant treatment, location of the neoplasm, duration of preoperative symptoms, patient's age at onset, preoperative condition, and cystic formation in the neoplasm also appeared to have a relationship, although it was slight.

show abstract

Section: *mentioning

confidence: 63%

Statistical analysis of factors affecting survival after glioblastoma multiforme

Takeuchi

Hoshino

1977

Acta neurochir

View full text Add to dashboard Cite

show abstract

“…There were other case series reported in the 1960s and 1970s that suggested a survival advantage with postoperative RT [7][8][9][10][11][12][13]. The interpretation of these early outcomes is complicated by the nonrandomized nature of these studies and inconsistencies in classification of glioblastoma.…”

Section: Establishing the Role Of Post-resection Rtmentioning

confidence: 99%

Radiation Therapy of Glioblastoma

Barani

Larson

2014

Cancer Treatment and Research

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common malignant brain tumor that affects approximately 17,000 patients annually. Clear survival advantages have been demonstrated with postoperative radiation therapy (RT) to doses of 5,000-6,000 cGy but dose-escalation attempts beyond 6,000 cGy have resulted in increased toxicity but no additional survival benefit. To improve local control and limit toxicity to normal brain tissue with these infiltrating tumors, novel imaging techniques are actively being explored to better define tumor extent and associated RT treatment fields. Hyperfractionated RT has been associated with a survival detriment. Current standard-of-care treatment involves concurrent use of temozolomide and RT to 6,000 cGy over 30 days followed by adjuvant temozolomide treatment for 6 months. Brachytherapy and stereotactic radiosurgery are effective therapies for relapsed GBM but tend to be associated with notable toxicity. More recently, re-irradiation strategies employ concurrent use of bevacizumab to limit treatment-related injury while still permitting delivery of meaningful doses. These clinical trials are ongoing and merits of these strategies are not yet clear but appear promising.

show abstract

“…In 1966, the Montreal Neurology Institute published the first large case series that suggested a survival advantage in patients who received an average total post-resection IR dose of 5,000-6,000 cGy 5 . Over the next decade, other case series corroborated those data, suggesting an improvement in patient survival with post-resection IR [6][7][8][9] . Although interpretation of these case series is confounded by their retrospective, non-randomized nature, and wide variations in radiation dose regimen, an overall trend of improved patient survival was seen.…”

Section: Introductionmentioning

confidence: 76%